We are living through the most significant platform shift since the Internet. Host Daniel Kazani talks with guest Shefqet Avdullau, an angel investor, advisor, and speaker focused on growth-stage B2B SaaS, FinTech, ad tech, and health tech. The conversation starts with a story that moves from coding to multiple ventures to a meaningful exit, then into investing with a mentor who gave a head start on due diligence, pitfalls, and strategies. The weight falls on the team because the idea you start with does not necessarily mean you will end with it, and a good team can turn a bad idea into a great one. Then: AI and defensibility, wrappers, data-loop strategy, fine-tuning, and what happens if OpenAI or Gemini releases a new update tomorrow. Health tech and biotech, drug discovery, and turning biology into an engineering problem. ㅤ 👤 Guest BioShefqet Avdullau is an angel investor, advisor, and speaker. He invests in serial founders across the US and UK, focusing on B2B SaaS, FinTech, and ad tech at all stages, and on health tech specifically at the growth stage. His foundation is in tech; he worked in that field for about 13 years, started multiple ventures with some small exits, and then had one meaningful exit. In about four years, he has done about 16 investments and has had two exits. ㅤ 📌 What We CoverFrom coding, to multiple ventures, to a meaningful exit, to investing and joining a group of investorsA mentor with private equity experience, due diligence, pitfalls in investing, and strategies to followWhy serial founders come with a map, with a playbook, and go straight to finding product market fitScars, lessons, when things get tough, and why failure can be something you preferIdea versus team, pivots, and why the team can turn a bad idea into a great ideaTwo founders or more, complementary skillset, product, and sales, and a third on operationsFounder problem fit, domain experience, network, and solving an actual problem, not just for moneyAI wrappers versus defensibility, data loop strategy, fine-tuning, and “would this company die” after a new updateWhere AI is disrupting, health tech and biotech, drug discovery, simulating millions of interactions digitally, and FinTech underwriting with unstructured dataUsing AI for competitor analysis, risk analysis, and alternative potential revenue streams, and “it hallucinates a lot”A contrarian investment choice, two serial founders, employee disengagement, productivity, and invisible frictions ㅤ 🔗 Resources MentionedOpen AIGeminiFigmaNvidiaLinkedInlovable
